RxDoctor Payments Data

Chiraag Patel, MD

Allergy & Immunology · Roseville, CANPI 1649426602

Payments from drug & device makers

$20,755in general payments, 2019–2025

Across 922 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • GSK$2K
  • Octapharma USA, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • CSL Behring$1K
  • Boehringer Ingelheim$1K
  • plus $8K from 53 others

What the payments were for

  • Food & beverage$20,40198%
  • Education$3552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,755 in reported general payments places this provider in the 80th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$1,141,610
Medicare patients
365
Services billed
56,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5048$450,355
XolairOmalizumab53$273,024
HyqviaIgg/Hyaluronidase,recombinant13$149,897
NucalaMepolizumab24$80,628
HizentraImmun Glob G(Igg)/Pro/Iga 0-5017$67,122
TezspireTezepelumab-Ekko16$66,049
Dupixent SyringeDupilumab14$51,026
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$44,121
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$36,350
Spiriva RespimatTiotropium Bromide17$23,926
SymbicortBudesonide/Formoterol Fumarate59$23,504
Epinephrine93$21,262
Arnuity ElliptaFluticasone Furoate31$14,903
BreynaBudesonide/Formoterol Fumarate53$14,375
Breo ElliptaFluticasone/Vilanterol14$11,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Hyqvia$1,496$600,25261 claims
GSKNucala, Trelegy Ellipta, Arnuity Ellipta, Breo Ellipta$2,292$143,321105 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$4,722$133,674115 claims
CSL BehringHizentra$1,337$67,12217 claims
Boehringer IngelheimSpiriva Respimat$1,157$23,92617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →